PDS Common Stock Total Equity from 2010 to 2025
| PDSB Stock | USD 1.36 0.01 0.73% |
Common Stock Total Equity | First Reported 2014-12-31 | Previous Quarter 10.1 K | Current Value 10.2 K | Quarterly Volatility 3.4 K |
Check PDS Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among PDS Biotechnology's main balance sheet or income statement drivers, such as Depreciation And Amortization of 62.6 K, Interest Expense of 5.1 M or Selling General Administrative of 11.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 5.56. PDS financial statements analysis is a perfect complement when working with PDS Biotechnology Valuation or Volatility modules.
PDS | Common Stock Total Equity |
Latest PDS Biotechnology's Common Stock Total Equity Growth Pattern
Below is the plot of the Common Stock Total Equity of PDS Biotechnology Corp over the last few years. It is the total value of common stock equity held by shareholders, representing their ownership interest in the company. PDS Biotechnology's Common Stock Total Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in PDS Biotechnology's overall financial position and show how it may be relating to other accounts over time.
| Common Stock Total Equity | 10 Years Trend |
|
Common Stock Total Equity |
| Timeline |
PDS Common Stock Total Equity Regression Statistics
| Arithmetic Mean | 6,387 | |
| Geometric Mean | 3,915 | |
| Coefficient Of Variation | 70.20 | |
| Mean Deviation | 4,091 | |
| Median | 9,720 | |
| Standard Deviation | 4,483 | |
| Sample Variance | 20.1M | |
| Range | 10.7K | |
| R-Value | 0.71 | |
| Mean Square Error | 10.8M | |
| R-Squared | 0.50 | |
| Significance | 0 | |
| Slope | 663.99 | |
| Total Sum of Squares | 301.5M |
PDS Common Stock Total Equity History
About PDS Biotechnology Financial Statements
PDS Biotechnology stakeholders use historical fundamental indicators, such as PDS Biotechnology's Common Stock Total Equity, to determine how well the company is positioned to perform in the future. Although PDS Biotechnology investors may analyze each financial statement separately, they are all interrelated. For example, changes in PDS Biotechnology's assets and liabilities are reflected in the revenues and expenses on PDS Biotechnology's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in PDS Biotechnology Corp. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Common Stock Total Equity | 11.4 K | 7.5 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out the analysis of PDS Biotechnology Correlation against competitors. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PDS Biotechnology. If investors know PDS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PDS Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of PDS Biotechnology Corp is measured differently than its book value, which is the value of PDS that is recorded on the company's balance sheet. Investors also form their own opinion of PDS Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is PDS Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PDS Biotechnology's market value can be influenced by many factors that don't directly affect PDS Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PDS Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if PDS Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PDS Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.